Beyond Air, Inc. (XAIR)
After hours:
| Previous Close | 1.0950 |
| Open | 1.1000 |
| Bid | 1.0900 x 300 |
| Ask | 1.1200 x 100 |
| Day's Range | 1.0600 - 1.1200 |
| 52 Week Range | 1.0600 - 6.3600 |
| Volume | |
| Avg. Volume | 309,179 |
| Market Cap | 50.72M |
| Beta (5Y Monthly) | -0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1300 |
| Earnings Date | Jun 24, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.67 |
GlobeNewswireBeyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast
Conference call scheduled for Monday, June 24th at 4:30 pm ETGARDEN CITY, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today
- GlobeNewswire
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
Company to host an event featuring key opinion leaders (KOLs) on Friday, May 31st in Chicago to highlight the ongoing clinical development of UNOHAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present on the clinical development program of its Ultra-High Concentration Nitric Oxide (UNO) at the upcoming A
- GlobeNewswire
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that it has entered into a securities purchase ag
